PALI
Palisade Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.09
+2.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 500.0K | — | — | 250.0K | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 500.0K | — | — | 250.0K | — |
| Operating Expenses | |||||
| R&D Expense | 21.4M | 10.2M | 9.1M | 6.9M | 6.5M |
| SG&A Expense | 14.5M | 7.9M | 5.8M | 6.2M | 8.8M |
| General & Admin Expense | 14.5M | 7.9M | 5.8M | 6.2M | 8.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | 225.0K | 410.0K |
| Total Operating Expenses | 35.8M | 18.1M | 14.9M | 13.3M | 15.7M |
| Cost and Expenses | 35.8M | 18.1M | 14.9M | 13.3M | 15.7M |
| Operating Income (EBIT) | (35.3M) | (18.1M) | (14.9M) | (13.1M) | (15.7M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 13.0K |
| Interest Expense | 6.0K | 10.0K | 12.0K | 15.0K | 13.0K |
| Net Interest Income | (6.0K) | (10.0K) | (12.0K) | (15.0K) | — |
| Other Non-Op Income/Expense | 3.4M | 1.3M | 421.0K | 770.0K | 1.5M |
| Non-Operating Income (excl Interest) | (2.1M) | (1.3M) | (433.0K) | (785.0K) | (1.5M) |
| EBT (Pre-Tax Income) | (31.9M) | (16.8M) | (14.4M) | (12.3M) | (14.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (31.9M) | (16.8M) | (14.4M) | (12.3M) | (14.3M) |
| Earnings from Cont. Ops | (31.9M) | (16.8M) | (14.4M) | (12.3M) | (14.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (31.9M) | (16.8M) | (14.4M) | (12.3M) | (14.5M) |
| Per Share | |||||
| Basic EPS | ($0.53) | ($0.30) | ($10.19) | ($27.01) | ($16.53) |
| Diluted EPS | ($0.53) | ($0.30) | ($10.19) | ($27.01) | ($16.53) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.55 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 211.4M | 55.7M | 1.4M | 456014 | 880095 |
| Diluted Shares Outstanding | 211.4M | 55.7M | 1.4M | 456014 | 880305 |
| Profitability Metrics | |||||
| EBITDA | (33.2M) | (16.8M) | (14.4M) | (12.3M) | (14.2M) |
| D&A | 1.0K | 3.0K | 3.0K | 4.0K | 3.0K |
| EBIT | (33.2M) | (16.8M) | (14.4M) | (12.3M) | (14.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026